Updated: August 12, 2024

Published: July 23, 2024

WHAT! Tissue Loss? InSphero Experts on Preventing Tissue Loss in Akura™ Spheroid Microplates

Preventing tissue loss during liquid exchange

Ensuring that spheroids are intact during liquid exchange is not fun and certainly not easy (contrary to what you will see in this video). That’s why we developed our Akura™ Microplates with a special feature to make your life much easier: The SureXchange™ well design enables optimal protection of the spheroids in a cavity at the bottom of the well during liquid exchange.

What else do you need to know to prevent tissue loss? Our Senior Product Manager, Dr. Frauke Greve, asked InSphero's 3D in vitro experts about their tips and tricks.

Tips for preventing tissue loss in Akura™ Spheroid Microplates

What kind of pipettes shall I use to perform medium exchange?

You can use single- or multi-channel pipettes as well as semi- or fully automated liquid handlers. For the Akura™ 96 Plate, we usually use multi-channel pipettes when we work with a lower number of plates, and semi-automated systems when handling larger amounts of plates. For the Akura™ 384 Plates, we only work with semi- or fully automated liquid handlers.

Where shall I place the pipette tip in the well to prevent tissue loss?

Place the pipette tip at the rim specifically designed for pipetting, which is called the SureXchange ™ ledge. In the Akura™ 96 Plate, the well has an axial symmetry (Image 1) whereas in the Akura™ 384 Plate the ledge is only located at one side of the well (asymmetric design - Image 2). Thus, your pipette tip is located as far away as possible from the spheroids to prevent accidental aspiration, and the spheroids are safely located in a small protective cavity at the bottom of the well.

Liquid exchange in Akura™ 96 Plate - prevent tissue loss

Image 1: Preventing tissue loss - Medium exchange in Akura™ 96 Spheroid Microplate

Liquid exchange in Akura™ 384 Plate - preventing tissue loss

Image 2: Preventing tissue loss - Medium exchange in Akura™ 384 Spheroid Microplate

How much medium is left after aspiration?

By placing the tip on the ledge, you can aspire medium without hesitance. During aspiration, surface tension leaves a defined minimal residual volume at the bottom of the well. The spheroid is protected from aspiration and high shear forces. This way, > 90% of medium can be reproducibly removed without losing spheroids. For the Akura™ 96 Plate, the remaining volume is approximately 5-7 µl, for the Akura™ 384 Plate approximately 3-5 µl medium is left in the lower cavity of the well.

What speed shall I use when aspirating and dispensing medium?

Remove the medium at low pipetting speed (< 20 µl/sec) by aspirating an excess of volume (i.e. 75 µl when using 70 µl medium per well). A minimal volume will remain in the well.
Add fresh medium (70 µl for the Akura™ 96, 50 µl for the Akura™ 384) at low pipetting speed by placing the pipette tip at the ledge. Use a dispensing rate of < 30 µl/sec to prevent turbulences in the wells and accidental floating of spheroids.

How often do you exchange medium?

Although we use an incubator with good humidity control (>95% of rel. humidity), and exercise best practice in maintaining and minimizing loss of humidity (e.g., minimize incubator door opening and closing), we can only reduce but not prevent evaporation of medium in the outer (perimeter) wells. Therefore, we exchange medium every 2-3 days, but that can be increased to every day if conditions require.

Read More

FDA Modernization Act 3.0
Blog

The FDA Modernization Act 3.0: Paving the Way for a New Era in Drug Development or a Gentle Nudge?

In a significant step toward making drug development more patient-centric, the FDA Modernization Act 3.0 was introduced as a major piece of forward-looking legislation in February 2024. For stakeholders across the biopharmaceutical industry, including companies like InSphero that specialize in complex in vitro models, this legislation presents both promising opportunities and new challenges. Will it change things?

Read the full blog post »
antisense oligonucleotides
Blog

Understanding the DILI Risks of Antisense Oligonucleotides and the Value of Predictive In Vitro Testing

Antisense oligonucleotides (ASOs) offer therapeutic avenues for diseases that are currently unmet by alternative therapeutic modalities. However, the development of therapeutic ASOs is often hampered by hepatotoxicity. In this blog, we explore why 3D human liver microtissues are becoming an indispensable tool for de-risking ASO drug candidates and for reducing attrition in late-stage drug development. 

Read the full blog post »
Testing Drug-induced Mitochondrial Toxicity in 3D InSight™ Human Liver Microtissues
Blog

Testing Drug-induced Mitochondrial Toxicity in 3D InSight™ Human Liver Microtissues

Toxicological studies show that drugs can alter mitochondrial functions, potentially resulting in a deleterious range of toxic reactions from the induction of micro- and macrovesicular steatosis to lactic acidosis. These clinical manifestations are the consequence of drugs interfering with four main mitochondrial functions or constituents: aerobic respiration, beta-oxidation, and mitochondrial DNA homeostasis.

Read the full blog post »
Scroll to Top

Your Success is Our Mission - Get in Touch

Fill in form below to contact our 3D in vitro experts

Sign up for our Newsletter

Get the latest news on 3D in vitro research

View resource

Fill in the form below to view this resource